Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5. Mark Rosenblum, chief financial officer, Dr. Daniela Santiesteban, director of targeted protein degradation development and Dr. Aundrietta Duncan, director of non-clinical development will host a virtual investor presentation followed by a question and answer session at 11:00 a.m. Eastern time. To participate, please click…
